Natera Partners With Incyte on Phase II Colorectal Cancer Study

• Natera entered a clinical collaboration with Incyte for a phase II colorectal cancer study.
• The trial will evaluate Incyte’s investigational bispecific immunotherapy INCA33890 in stage 2/3 patients who completed surgery and adjuvant chemotherapy.
• Signatera testing will continue for up to 12 months following chemotherapy, with results incorporated as primary and secondary trial endpoints.
• Patients testing positive for molecular residual disease without radiographic evidence of disease may qualify for enrollment and treatment.
• The collaboration includes trial-matching services to identify eligible patients based on Signatera results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611100700BIZWIRE_USPR_____20261110_BW610640) on November 10, 2026, and is solely responsible for the information contained therein.